Daniela Bota

Has grant

Associate Dean, Clinical Research

University of California, Irvine

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Daniela Bota is the Associate Dean of Clinical Research at the University of California Irvine, USA. Her research focuses on glioblastoma, tumor immunotherapy, and neuro-oncology, as evidenced by her recent articles exploring dendritic cell vaccines and chemotherapeutic resistance. Additionally, she investigates the implications of signaling pathways in chemotherapy-induced neuropathy and evaluates innovative treatment strategies for meningioma and neurofibromatosis.

Recent Grants

Grant: Close

Preclinical development of ampakines for Chemo Brain

Open Date: 2017-01-01

Close Date: 2018-07-31

Grant: Close

Mechanisms of Chemotherapy Induced Cognitive Defects

Open Date: 2011-08-15

Close Date: 2017-03-31

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (3)

Yue Lu

Assistant Professor

University of Utah

UNITED STATES

View details

Luca Bertero

Associate professor of Pathology

University of Turin

ITALY

View details

Torstein R. Meling

Head of department

DENMARK

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Daniela Bota

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (20)

The concept, intention, and evaluation of the term treatment-refractory meningioma

Phase 2 trial of personal dendritic cell vaccines in newly diagnosed glioblastoma: 3-year follow-up and correlations with survival

Glioma chemotherapeutic resistance is tied to membrane electrophysiological properties and glycosylation

A Digital Asthma Self-Management Program for Adults

Dual targeting of the mitochondrial Lon peptidase 1 and the chymotrypsin-like proteasome activity as a potential therapeutic strategy in malignant astrocytoma models

Neuronal p38 MAPK Signaling Contributes to Cisplatin-Induced Peripheral Neuropathy

ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma

N-acetylcysteine prevents cisplatin-induced cognitive impairments in an ovarian cancer rat model

Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H

Randomized phase IIb trial of a CMV vaccine immunotherapeutic candidate (VBI-1901) in recurrent glioblastomas.

Cisplatin induces BDNF downregulation in middle-aged female rat model while BDNF enhancement attenuates cisplatin neurotoxicity

Abstract 3180: Suppression of the CPEB3 ribozyme modulates the progression of glioblastoma

Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial

Next-generation vaccines are showing promise against glioblastoma

CTIM-29. TUMOR RESPONSES IN A RANDOMIZED PHASE IIB TRIAL OF A CMV VACCINE IMMUNOTHERAPEUTIC CANDIDATE (VBI-1901) IN RECURRENT GLIOBLASTOMAS

BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas.

Identification of new hit to lead magmas inhibitors as potential therapeutics for glioblastoma

Final results of phase 2 trial of personal dendritic cell (DC) vaccines loaded with autologous tumor antigens (ATA) in newly diagnosed glioblastoma (GBM).

Cisplatin Induces BDNF Downregulation in Middle-Aged Female Rat Model while BDNF Enhancement Attenuates Cisplatin Neurotoxicity

Non-viral precision T cell receptor replacement for personalized cell therapy

Collaborators (3)

Yue Lu

Luca Bertero

Torstein R. Meling

Make your next move.